Astrocytoma, IDH-mutant, grade 4

Researchers are testing whether combining valproic acid, irinotecan, and simvastatin can shrink or stabilize recurrent glioblastoma and IDH-mutated glioma tumors. The trial enrolls 52 adults whose tumors have grown after prior treatment with radiation and chemotherapy. Participan…

This early-stage trial tests genetically engineered natural killer (NK) cells in 25 people with recurrent glioblastoma, an aggressive brain cancer. The cells are designed to resist the tumor's defenses. The main goal is to find a safe dose and check for side effects, while also w…

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…

This early-stage trial tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. Researchers will give patients specially engineered natural killer (NK) cells, either directly into the brain or through an …

This early-phase trial tests the safety of a new treatment for people with recurrent or progressive high-grade glioma, a serious brain cancer. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into t…

This early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study…

This phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cell…

This study tests two drugs—retifanlimab (an immunotherapy) and DFMO (a growth blocker)—alone or together in 33 adults with progressive high-grade glioma, an aggressive brain cancer. The goal is to find the safest, most effective dose and see if the combination boosts the immune s…

This phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells i…

This early-stage trial tests whether stem cells taken from fat tissue can be safely injected into the brain during surgery for recurrent glioblastoma. The stem cells are meant to attack remaining tumor cells and make them more sensitive to chemotherapy. About 20 adults whose brai…

This trial is testing two experimental drugs, avutometinib and defactinib, alone or with a standard chemotherapy (temozolomide), in people with high-grade malignant brain tumours like glioblastoma. The study aims to find a safe dose and see if the drugs can shrink tumours or stop…